DayTwo
DayTwo uses advanced microbiome analysis and AI technology to provide personalized nutrition plans for managing chronic diseases such as type 2 diabetes, achieving significant health improvements.
Company Overview
DayTwo uses microbiome data to address chronic diseases, with a focus on type 2 diabetes. The company provides personalized nutrition plans based on individual microbiome analysis. Utilizing a patented AI, DayTwo predicts blood sugar responses before eating, aiding in better health management for their users.
Personalized Nutrition Plans
DayTwo offers personalized nutrition plans tailored to individual microbiome profiles. These plans are designed to manage and improve health, particularly for individuals with type 2 diabetes. The approach is rooted in advanced microbiome analysis, which allows for precise recommendations that can significantly impact users' wellbeing.
AI Technology for Blood Sugar Prediction
DayTwo employs a patented AI technology to predict blood sugar responses before eating. This innovative approach helps users make informed dietary choices to manage their condition effectively. The AI analyzes microbiome data to offer accurate predictions that help in maintaining stable blood sugar levels.
Clinical Outcomes and Member Support
DayTwo reports significant clinical outcomes for its users, including an average drop of 1.1 in A1C, 85% average time-in-range, 12 lbs average weight loss, and a 34% reduction in medication. The company also provides ongoing individualized support from registered dietitians and care teams, ensuring members receive continuous, personalized care.
Research and Clinical Validation
DayTwo's approach is validated by hundreds of peer-reviewed studies and ongoing clinical research. The company uses the highest-resolution microbiome analysis available. The program outcomes are based on a 12-month national book of business as of March 2022, showcasing its effectiveness and reliability in managing chronic diseases.